Overview
SNY market data
Price History
SNY price chart · 1M
- O
- 44.85
- H
- 45.08
- L
- 44.74
- C
- 44.85
- Vol
- 135,418.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $44.85
- Previous Close
- $45.44
- Day High
- $45.08
- Day Low
- $44.74
- 52 Week High
- $46.11
- 52 Week Low
- $40.90
- 7 Day Return
- -0.61%
- 30 Day Return
- -1.50%
- 90 Day Return
- +2.64%
- 1 Year Return
- +1.28%
- Daily Notional Volume
- $6.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 16.24 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.37 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.77 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 9.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $71.25 – $91.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $90.5B · P/B 1.41 · P/S 1.50.
Company News
$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, ChallengesGlobenewswire Inc · Aug 26, 2026, 2:15 PM
AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma PlayersGlobenewswire Inc · Aug 25, 2026, 5:15 PM
Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine PolicyBenzinga · Aug 24, 2026, 1:28 PM
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent IndicationBenzinga · Aug 18, 2026, 2:46 PM
EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24Benzinga · Aug 18, 2026, 11:18 AM
Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED)Benzinga · Aug 11, 2026, 3:01 AM
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other PlayersGlobenewswire Inc · Aug 7, 2026, 11:00 AM
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911Benzinga · Aug 4, 2026, 11:14 AM
Sanofi Secures EU Approval For MenQuadfi In Infants From Six Weeks, Backed By Immunogenicity Data From Pivotal MET58 StudyBenzinga · Aug 4, 2026, 5:20 AM